Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype

Nicolas Pallet, Isabelle Etienne, Matthias Buchler, Éric Bailly, Bruno Hurault de Ligny, Gabriel Choukroun, Charlotte Colosio, Antoine Thierry, Cécile Vigneau, Bruno Moulin, et al.

HAL Id: hal-01296771

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01296771

Submitted on 8 Jun 2016

Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to *CYP3A5* Genotype

N. Pallet[1,2,3,4,*], I. Etienne[5], M. Buchler[6], E. Bailly[6], B. Hurault de Ligny[7], G. Choukroun[8], C. Colosio[9], A. Thierry[10], C. Vigneau[11], B. Moulin[12], Y. Le Meur[13], A.-E. Heng[14], C. Legendre[15], P. Beaune[1,3,4], M. A. Loriot[1,3,4] and E. Thervet[2,3,4]

1 Clinical Chemistry Department, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France
2 Department of Nephrology, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France
3 Paris Descartes University, Paris, France
4 Sorbonne Paris Cité, INSERM UMRS 1147, Paris, France
5 Department of Nephrology-Clinical Immmunology, CHU Rouen, Rouen, France
6 Department of Nephrology, CHU Tours, Tours, France
7 Department of Nephrology, CHU Caen, Caen, France
8 Department of Nephrology, CHU Amiens, Amiens, France
9 Department of Nephrology, CHU Reims, Reims, France
10 Department of Nephrology, CHU Poitiers, Poitiers, France
11 Department of Nephrology, CHU Rennes, Rennes, France
12 Department of Nephrology, CHU Strasbourg, Strasbourg, France
13 Department of Nephrology, CHU Brest, Brest, France
14 Department of Nephrology, CHU Clermont-Ferrand, Clermont-Ferrand, France
15 Department of Nephrology, Necker Hospital, Assistance Publique Hôpitaux de Paris, Paris, France

[*]Corresponding author: Nicolas Pallet, npallet@yahoo.fr

Abbreviations

AMR : antibody mediated rejection
C_0 : trough blood concentrations
CYP3A5 : cytochrome P450 3A5

Abstract

Pretransplantation adaptation of the daily dose of tacrolimus to *CYP3A5* genotype is associated with improved achievement of target trough concentration (C_0), but whether this improvement affects clinical outcomes is unknown. In the present study, we have evaluated the long-term clinical impact of the adaptation of initial tacrolimus dosing according to *CYP3A5* genotype: the transplantation outcomes of the 236 kidney transplant recipients included in the Tactique study were retrospectively investigated over a period of more than 5 years. In the Tactique study, patients were randomly assigned to receive tacrolimus at either a fixed dosage or a dosage determined by their genotype, and the primary efficacy end point was the proportion of patients for whom tacrolimus C_0 was within target range (10–15 ng/ml) at day 10. Our results indicate that the incidence of biopsy proven acute rejection and graft survival were similar between the control and the adapted tacrolimus dose groups, as well as between the patients who achieve the tacrolimus C_0 target ranges earlier. Parients death, cancer, cardiovascular events and infections were also similar, and renal function did not change. We conclude that optimization of initial tacrolimus dose using pharmacogenetic testing does not improve clinical outcomes.

Introduction

The calcineurin inhibitor tacrolimus is a key component of modern immunosuppression protocols in kidney transplantation (1). Together with its narrow therapeutic window, the great inter-individual variability in tacrolimus pharmacokinetic parameters are majors concerns, and the relationship between tacrolimus trough blood concentrations (C_0) with toxicity and rejection fostered the development of biomarkers that would help to individualize drug dosage in predicting the pharmacokinetic responses *(2, 3)*. Numerous intrinsic and extrinsic parameters influence tacrolimus pharmacokinetic parameters, and variations in the expression and/or activity of drug metabolizing enzymes and transporters, in general supported by single nucleotide variants (SNVs), received much attention over the 15 last years (4). Of particular importance is the impact of variants in the genes encoding P450 cytochromes 3A (*CYP3A4* and *3A5*), which control tacrolimus hepatic metabolism and intestinal absorption, in tacrolimus pharmacokinetic profiles (5, 6), and a large body of evidence has validated the effects mediated by the SNV at position 6986 of the *CYP3A5* gene (rs776746; 6986A>G) (7). This variant causes a splicing defect resulting in the absence of functional CYP3A5 protein (8). Patients who are homozygous for the 6986 G allele (designated as *CYP3A5*3*) are therefore expected to lack CYP3A5 activity and require higher tacrolimus dose to reach the target C_0 range.

The rationale for the adaptation of initial tacrolimus dose using pharmacogenetic testing of *CYP3A5* genotypes in kidney transplantation is supported by the theoretical risk of increased rejection episodes in patients who failed to reach therapeutic tacrolimus C_0 ranges early after transplantation, for example the *CYP3A5*1/*1* carriers (expressers) in whom higher dose requirement may cause a delay in reaching the desired C_0 (9-11) even though this concept has been recently challenged (12). Nevertheless, there is now a relative consensus on the fact that pharmacogenetic adaptation of the

daily dose of tacrolimus to *CYP3A5* genotype might improve achievement of the target C_0, but that this strategy actually fails to improve short-term (up to three months) transplantation outcomes, including rejection, delayed graft function and acute nephrotoxicity (7, 13).

The critical point that remains, and that has never been investigated, is whether genotyping kidney transplant candidates for *CYP3A5* variants improved the long-term clinical outcomes after transplantation, and this information is crucial for advocating the implementation of routine testing of *CYP3A5* in kidney transplantation. To address this issue, we have investigated the results of the Tactique study, which was initially undertaken to test whether pharmacogenetic adaptation of the daily dose of tacrolimus is associated with improved achievement of the target C_0 (14), over a period of more than 5 years.

Patients and methods

Study design

The Tactique study, a prospective and multicenter trial, was conducted in 2006 and 2007 to evaluate whether adaption of tacrolimus dosing according to the *CYP3A5* genotype would allow earlier achievement of tacrolimus C_0 in kidney transplant recipients. The design of the study is detailed in (14). Included patients were randomly assigned at day 7 post transplantation to receive tacrolimus at either a fixed dosage of 0.2 mg/kg/day (the control group, n=120) or a dosage determined by their genotype: CYP3A5 expressers (i.e., carriers of the *CYP3A5*1* allele) received 0.3 mg/kg/day, whereas CYP3A5 non-expressers (*CYP3A5*3/*3* genotype) received 0.15 mg/kg/day (the adapted-dose group, n=116). The first measurement of C_0 was performed after the intake of six doses (=day 10 after transplantation) and the primary efficacy end point was the proportion of patients for whom tacrolimus C_0 was within target range (10–15 mg/l) at day 10. All patients received a biological induction (16% basiliximab, 84% rabbit thymocyte antiglobulin), 3g of mycophenolate mofetil (Cell-Cept; Roche, Basel, Switzerland) daily for 15 days (tapered to 2 g/day) and a tapered corticosteroid regimen.

For the long-term follow-up study presented here, we investigated the medical records of all the patients analyzed on the basis of the intention-to-treat principle in the Tactique study, and for whom the graft and/or life status was available at the date of September 1, 2015. This information was lacking in 24 out of the 236 patients, which were excluded from the study. Research assistants within each center who participated to the initial Tactique study manually retrieved clinical and biological parameters. This study was approved by the institutional review board at each participating center, and written informed consent was obtained from all patients. The study was carried out in compliance with the provisions of the Declaration of Helsinki, and the Declaration of Istanbul on Organ Trafficking and Transplant Tourism.

Statistical analyses

Demographic and baseline characteristics were summarized as counts and percentages for categorical variables, and continuous variables as means±standard deviation.
To address the long-term outcome of the optimization of initial tacrolimus dose using pharmacogenetic testing on the basis of the Tactique study, we compared the primary and secondary end-points in groups according to (1) the randomization arm (ie. adapted versus control groups), and to (2) the success versus failure of the primary end point, which was the proportion of patients for whom tacrolimus C_0 was within target range (10–15 ng/ml) after six oral doses. Hence,

such comparisons would provide information of the clinical impact of adapting tacrolimus doses according to *CYP3A5* genotype, and determine whether reaching target tacrolimus C_0 range at an earlier time point after the transplant could improve graft outcomes.

The primary outcome of this follow-up study was the incidence of graft loss over time, which was estimated with Kaplan-Meier survival analysis, and compared between groups using the Log Rank test. Secondary end-points were clinical parameters including incidence of biopsy-proven acute rejection, patient death, cardiovascular events, cancers, and infections, and biological parameters including proteinuria, graft function, and hemoglobin A1c at the last follow-up visit. Categorical data were compared using Chi square test; continuous variables were compared using the Student's t-test. The incidences of graft loss and biopsy-proven graft rejection were estimated using Kaplan–Meier curves. All tests were two tailed, and a P value <0.05 was considered statistically significant. All analyses were performed using JMP.10.0.0 (SAS corporation).

Results

Patients demographics and baseline characteristics

The initial intention-to-treat population of the Tactique study was made of 236 individuals (120 in the control group, and 116 in the adapted dose group) (14). All patients from this population for who graft and/or living status were available at the date of September 1, 2015 were included for the present follow-up study, and 24 out of the 236 patients were lost to follow-up. Consequently, the final study population was made of 212 patients: 104 in the control group and 108 in the adapted dose group. The characteristics of this population of according to the randomization arms are detailed on the **Table 1.** The two groups of patients were comparable regarding the recipients and donors demographic and clinical characteristics. As expected, the proportion of patients who reached the primary end-point was still significantly higher in the adapted-dose group compared with the control group (42% versus 25%, p=0.01, Chi square test), indicating that the loss of patients in the follow-up study did not skew the study population.

Pharmacogenetic adaptation of the daily dose of tacrolimus does not impact rejection rates and graft survival.

To test whether pharmacogenetic adaptation to *CYP3A5* genotype of the daily dose of tacrolimus influences transplantation outcomes, we compared the incidence of kidney allograft loss over time between the control and the adapted groups. The Kaplan-Meier curves in the **Figures 1 A and B** indicate that graft survivals (including death-censored) are strictly comparable between the two groups of patients. Similarly, the incidence of biopsy-proven acute rejection was not different over time between the two groups (**Figure 1C**). Since the rate of success of the primary end-point was the only statistically different parameter between the two groups (**Table 1**), we also tested whether this parameter could impact graft survival and rejection incidence. Again, the incidence of graft loss and rejection among patients who reach tacrolimus C_0 target range earlier were similar to patients who did not (**Figure 1 D and E**).

Pharmacogenetic adaptation of the daily dose of tacrolimus does not impact graft outcomes

We next evaluated whether pharmacogenetic adaptation of the starting dose of tacrolimus after kidney transplantation provided better outcomes. The occurrence of adverse events related to renal transplantation, including cancers, infections and cardiovascular events in the study population was

in accordance with the literature (11). Indeed, the prevalence of cancer was 21%, infections 47%, and cardiovascular events 20%. Seventeen (8%) of the patients died during the follow-up period. We did not found any significant difference between the control group and the adapted tacrolimus dose group, in terms of death, cancer, infection and cardiovascular events (**Table 2**). In addition, there was no significant between-group difference regarding renal function, proteinuria or blood pressure (**Table 2**). Similarly, we found no difference between patients who reached tacrolimus C_0 target range earlier and patients who did not reach the tacrolimus C_0 range in terms of adverse events or renal function (**Table 3**).

Discussion

Our results indicate that, on the basis of the long-term follow-up of patients included in the Tactique study, tacrolimus dosage adaptation to *CYP3A5* does not improve graft survival, rejection rates and adverse events related to transplantation. Even if these results do not support routine testing for *CYP3A5* genotypes prior to transplantation, caution must be paid before generalizing them because of the specificities of the Tactique protocol that may not be representative of the usual kidney transplant donor/recipients characteristics. Indeed, patients included in this study were highly selected with no expanded criteria donors, and had a low immunological risk. Even if the immunosuppressive regiment was the standard (corticosteroids, mycophenolate mofetil and tacrolimus), the target tacrolimus C_0 were higher than those currently recommended, notwithstanding that the optimal C_0 ranges for preventing rejection are not defined (15, 16). Most of the patients received induction with thymoglobulin and high mycophenolate dosages, despite a low immunological risk (to allow the delay of the introduction of tacrolimus), which may participate in the low rejection rate (<10%) and the very good results in terms of graft survival in the whole cohort (90% at five years, 80% at nearly 10 years). Given the low occurrence rate of the primary outcome of this follow-up study (graft loss), one must acknowledge that a larger population would have been required to detect a small effect (if any) of tacrolimus adaptation to *CYP3A5* genotype on graft survival. Of the patients lost to follow-up there were twice as many (16) in the control group as in the adapted dose group (8), and the difference between proportions of patients achieving the primary end-point was greater in the follow-up cohort than in the primary study which can generate a potential survivorship bias. However, that would have been expected to bias in favor of a positive result. One other limitation is the relatively lower proportion of CYP3A5 expressers based on the ethnicity of the study population, and, it is possible the results might be different in a population with a higher number of CYP3A5 expressers.

The rationale for adapting tacrolimus dosage to *CYP3A5* genotype was based in the assumption that tacrolimus underexposure in the first days after transplantation increases the risk of acute cellular rejection, and that would be relevant for patients who express CYP3A5 (*CYP3A5*1/*1*) and require higher doses (10). In addition, tacrolimus overexposure would foster chronic nephrotoxicity (7). Nevertheless, these hypothesis have never been formally validated, and despite a large number of studies and meta-analysis having addressed the question, whether *CYP3A5* genotype constitute a risk factor for adverse graft outcomes is still awaiting confirmation (7, 13, 17). In a conceptual point-of-view, if a parameter, namely the *CYP3A5* expresser genotype, is not formally validated and universally accepted as a risk factor for adverse outcomes, there is no obvious reason for that efforts engaged to anticipate the effects of the presence of this risk factor in a population would succeed to improve the outcome.

If dosing tacrolimus based on *CYP3A5* genotype does not improve clinical outcomes, the rationale for pharmacogenetic testing in kidney transplantation must be re-assessed taking into account that kidney transplantation is an evolving field, with highly controversial paradigms, like the causes of graft loss, or the role (and the definition) of calcineurin inhibitors nephrotoxicity, for a few examples. Therefore, the risk factors for adverse outcomes are constantly remodeling, and we believe that the next developments in kidney transplantation epidemiology should support an integrative approach that would include demographic, clinical and biological parameters to generate risk scores and subpopulations of patients at risk, rather than focusing on a single parameter (18). We believe that pharmacogenetic markers could be integrated in this process, and should not only include *CYP3A5* variants, but also *CYP3A4*22*, perhaps *POR*28 (*P450 oxydoreducase) and *ABCB1* (ATP Binding Casette 1) (9). In addition, donor genotypes for *ABCB1* and *CYP3A5*, which impact calcineurin inhibitors nephrotoxicity, should also be taken into account (19, 20).

In general, selective pharmacogenetic markers are successfully incorporated into clinical practice if they are able to predict a potentially fatal side effect (for example dihydropyrimidine dehydrogenase gene variants and 5 fluorouracil toxicity (21)) or a clinical response (for example Kras mutations and response to cetixumab (22)) with a strong association with the genotype. Such genetic markers are not available for the immunosuppressive agents armamentarium used in clinical transplantation. A promising perspective for pharmacogenetic testing implementation in clinical transplantation could be the identification of drug-response markers of antibody-mediated rejection treatments, to rationalize the cost-effectiveness of the treatments.

In conclusion, we have provided evidence that initial dosing of dosing tacrolimus based on *CYP3A5* genotype prior to transplantation does not improve clinical outcomes over the long term. Pharmacogenetic testing in kidney transplantation should be reconsidered in the light of the profound changes that operated in the last ten years in the way we understand the pathophysiology of allograft nephropathy, in the development of the immunosuppressive agents targeting AMR, and in the development of integrative epidemiology for assessing transplantation outcomes.

Disclosure

Figure legend

Figure 1: Impact of pharmacogenetic adaptation of the daily dose of tacrolimus on rejection rates and graft survival. (A) Kaplan–Meier survival curves for the association between control and adapted tacrolimus doses groups at different time points after transplantation and graft survival in the cohort of 212 patients. (B) Kaplan–Meier death censored survival curves for the association between control and adapted tacrolimus doses groups at different time points after transplantation and graft survival in the cohort of 212 patients. (C) Kaplan–

Meier survival curves for the association between control and adapted tacrolimus doses groups at different time points after transplantation and the incidence of biopsy-proven acute cellular rejection (BPAR) in the cohort of 212 patients. (D) Kaplan–Meier survival curves for the association between patients who reached or not the primary endpoint of the Tactique study at different time points after transplantation and graft survival in the cohort of 212 patients. (E) Kaplan–Meier death censored survival curves for the association between patients who reached or not the primary endpoint of the Tactique study at different time points after transplantation and graft survival in the cohort of 212 patients.

References

1. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357(25):2562-2575.
2. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002;359(9308):741-746.
3. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009;31(2):139-152.
4. Elens L, Hesselink DA, van Schaik RH, van Gelder T. Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications. Mol Diagn Ther 2012;16(6):331-345.
5. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003;76(8):1233-1235.
6. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011;57(11):1574-1583.
7. Rojas L, Neumann I, Herrero MJ, Boso V, Reig J, Poveda JL et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J 2015;15(1):38-48.
8. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27(4):383-391.
9. Elens L, Bouamar R, Shuker N, Hesselink DA, van Gelder T, van Schaik RH. Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. Br J Clin Pharmacol 2014;77(4):715-728.
10. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004;4(6):914-919.
11. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9 Suppl 3:S1-155.
12. Shuker N, Bouamar R, van Schaik RH, Clahsen-van Groningen MC, Damman J, Baan CC et al. A Randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with bodyweight-based tacrolimus dosing after living donor kidney transplantation. Am J Transplant 2015.
13. Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genazzani AA. The effect of

CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. Pharmacogenet Genomics 2012;22(8):642-645.

14. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010;87(6):721-726.

15. Bouamar R, Shuker N, Hesselink DA, Weimar W, Ekberg H, Kaplan B et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(dagger). Am J Transplant 2013;13(5):1253-1261.

16. Ekberg H, Mamelok RD, Pearson TC, Vincenti F, Tedesco-Silva H, Daloze P. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. Transplantation 2009;87(9):1360-1366.

17. Gijsen VM, Madadi P, Dube MP, Hesselink DA, Koren G, de Wildt SN. Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann Transplant 2012;17(2):111-121.

18. Storset E, Asberg A, Skauby M, Neely M, Bergan S, Bremer S et al. Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. Transplantation 2015;99(10):2158-2166.

19. Bloch J, Hazzan M, Van der Hauwaert C, Buob D, Savary G, Hertig A et al. Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients. Pharmacogenomics 2014;15(16):2011-2024.

20. Moore J, McKnight AJ, Dohler B, Simmonds MJ, Courtney AE, Brand OJ et al. Donor ABCB1 variant associates with increased risk for kidney allograft failure. J Am Soc Nephrol 2012;23(11):1891-1899.

21. Lunenburg CA, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JH et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer 2015;54:40-48.

22. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66(8):3992-3995.

23. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100(5):1059-1070.

Table 1. Recipients and donors baseline characteristics
Continuous variables are presented as mean±standard deviation; nominal variables are presented as n and percentage

	Control group (n=104)	Adapted dose group (n=108)	P value
Age of recipient (years)	45±1.2	47±1.2	0.2
Male recipient-n(%)	74 (71)	71 (65)	0.7
Caucasian origin-n(%)	77 (90)	77 (88)	0.8
Initial Renal disease diagnosis-n(%)			0.6
Cystic	20 (19)	25 (23)	
Diabetes	4 (3)	3 (3.5)	
Glomerulonephritis	33 (32)	31 (29)	
Hypertension	10 (9.5)	9 (8.5)	
Interstitial nephritis	13 (13)	9 (8.5)	
Other/unknown	24 (23)	33 (30)	
Donor age (years)[¶]	46.7±1.3	46.7±1.3	0.9
Donor male sex-n(%)	67 (65)	64 (60)	0.3
Previous transplantation-n(%)	6 (6)	6 (5.5)	0.9
Cause of death			0.4
Trauma	33 (34)	35 (34)	
Cerebrovascular event	48 (49)	43 (42)	
Other	16 (16)	24 (23)	
Cold ischemia time (hrs)	15.6±0.6	15.8±0.6	0.7
CYP3A5 genotype			0.4
1/1	6 (5.5)	4 (3.5)	
1/3	15 (14.5)	22 (20)	
3/3	83 (80)	82 (75)	
Primary end point success*-n(%)	26 (25)	46 (42)	0.01

* Tacrolimus C_o within the target range of concentration [10-15ng/mL] 10 days after transplantation
¶ Only deceased donors.

Table 2. Study secondary end points according to the randomization arm
Continuous variables are presented as mean±standard deviation; nominal variables are presented as n and percentage

	Control group (n=104)	Adapted dose group (n=108)	P value
Events			
Death-n(%)	6 (6)	11 (10)	0.2
Cancer-n(%)	15 (20)	17 (21)	0.8
Infection-n(%)	41 (55)	45 (50)	0.5
Cardiovascular events-n(%)	13 (17)	16 (20)	0.6
De novo donor specific antibodies-n(%)	15 (15)	23 (22)	0.2
Last follow-up visit			
Time after transplantation (months)	80±2.4	85±2.3	0.15
Weight (kg)	84±5.2	74±5	0.9
Systolic blood pressure (mmHg)	136±2	135±2	0.6
Diastolic blood pressure (mmHg)	79±1	78±1	0.6
Tacrolimus C_0/dose (ng/ml)/(mg)	1.5±0.2	1.6±0.3	0.15
Serum creatinine (μmol/l)	172±19	175±18	0.9
Hemoglobin A1c (%)	5.7±0.15	6.2±0.15	0.06
Proteinuria (g/l)	0.7±0.1	0.7±0.1	0.8

Table 3. Study secondary end points according to the primary end point of the Tactique study

Continuous variables are presented as mean±standard deviation; nominal variables are presented as n and percentage

	Success group (n=73)	Failure group (n=139)	P value
Events			
Death-n(%)	5 (7)	12 (8)	0.6
Cancer-n(%)	10 (19)	20 (22)	0.7
Infection-n(%)	55 (53)	26 (50)	0.5
Cardiovascular events-n(%)	11 (21)	18 (17)	0.6
De novo donor specific antibodies-n(%)	26 (20)	12 (17)	0.6
Last follow-up visit			
Time after transplantation (months)	83±2	82±2	0.6
Weight (kg)	74.3±6	81.9±4	0.3
Systolic blood pressure (mmHg)	138±2	134±1	0.2
Diastolic blood pressure (mmHg)	81±1	79±1	0.5
Tacrolimus C_0/dose (ng/ml)/(mg)	1.4±0.2	1.6±0.1	0.3
Serum creatinine (μmol/l)	156±22	183±16	0.3
Hemoglobin A1c (%)	6±0.1	5.6±0.1	0.06
Proteinuria (g/l)	0.9±0.2	0.6±0.1	0.8

FIGURE 1

A

Graft survival

| Control group |
| Adapted dose group |

p=0.73, Log Rank Test

Time since transplantation
(months)

| At risk, control group | 104 | 102 | 98 | 94 | 89 | 76 |
| At risk, adapted dose group | 108 | 106 | 106 | 97 | 89 | 76 |

B

Graft survival
(death censored)

| Control group |
| Adapted dose group |

p=0.66, Log Rank test

Time since transplantation
(months)

| At risk, control group | 98 | 95 | 94 | 91 | 87 | 77 |
| At risk, adapted dose group | 97 | 96 | 95 | 90 | 88 | 76 |

C

BPAR-free survival

| Control group |
| Adapted dose group |

p=0.2, Log Rank test

Time since transplantation
(months)

| At risk, control group | 101 | 94 | 90 | 87 | 85 | 75 |
| At risk, adapted dose group | 107 | 94 | 92 | 89 | 84 | 76 |

D

Graft survival
(death censored)

| Primary end point failure |
| Primary end point succes |

p=0.74, Log Rank test

Time since transplantation
(months)

| At risk, success group | 68 | 66 | 65 | 63 | 60 | 52 |
| At risk, failure group | 127 | 125 | 125 | 118 | 115 | 98 |

E

BPAR-free survival

| Primary end point failure |
| Primary end point succes |

p=0.2, Log Rank test

Time since transplantation
(months)

| At risk, control group | 101 | 94 | 90 | 87 | 85 | 75 |
| At risk, adapted dose group | 107 | 94 | 92 | 89 | 84 | 76 |